XIANGYU MEDICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.91 CNY | -2.92% |
|
-2.48% | -26.98% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 903M 125M 171M | Sales 2025 * | 1.11B 153M 209M | Capitalization | 6.11B 845M 1.16B |
|---|---|---|---|---|---|
| Net income 2024 * | 280M 38.71M 52.96M | Net income 2025 * | 338M 46.72M 63.93M | EV / Sales 2024 * | 6.77 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 5.53 x |
| P/E ratio 2024 * |
22.2
x | P/E ratio 2025 * |
18.4
x | Employees | 1,819 |
| Yield 2024 * |
1.58% | Yield 2025 * |
1.95% | Free-Float | 21.23% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.92% | ||
| 1 week | -2.48% | ||
| Current month | -2.48% | ||
| 1 month | -6.94% | ||
| 3 months | -6.31% | ||
| 6 months | -23.65% | ||
| Current year | -26.98% |
1 week
38.70
41.13
1 month
35.0242.26
Current year
32.5954.00
1 year
32.5958.43
3 years
25.20124.87
5 years
25.20124.87
10 years
25.20124.87
| Managers | Title | Age | Since |
|---|---|---|---|
Yong Zheng He
CEO | Chief Executive Officer | 52 | 02-03-19 |
Zhi Feng Li
CHM | Chairman | 38 | 14-04-30 |
Hongfeng Jin
DFI | Director of Finance/CFO | 50 | 23-04-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong Zheng He
CEO | Chief Executive Officer | 52 | 02-03-19 |
Jun Ling Guo
BRD | Director/Board Member | 51 | 12-07-31 |
Jue Wang
BRD | Director/Board Member | 69 | 18-12-23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.63% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 38.91 | -2.92% | 762,217 |
| 24-05-09 | 40.08 | -0.15% | 639,949 |
| 24-05-08 | 40.14 | -1.42% | 814,958 |
| 24-05-07 | 40.72 | +0.54% | 755,301 |
End-of-day quote Shanghai S.E., May 09, 2024
More quotes
Xiangyu Medical Co Ltd is a China-based company mainly engaged in rehabilitation medical equipment industry. The Company is mainly engaged in the independent research and development, production and marketing of intelligent rehabilitation equipment in the rehabilitation fields such as pain, neurology, orthopedics, traditional Chinese medicine, postpartum field, postoperative field, cardiopulmonary field, and medical-care integration. The Company's main products are divided into three categories: rehabilitation assessment, rehabilitation training, and rehabilitation physiotherapy. The Company mainly conducts business within the domestic market.
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
38.91
CNY
Average target price
50.78
CNY
Spread / Average Target
+30.51%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -26.98% | 846M | |
| +11.73% | 226B | |
| +9.53% | 188B | |
| +14.63% | 137B | |
| +27.47% | 108B | |
| +0.53% | 63.19B | |
| +13.73% | 52.26B | |
| +4.86% | 51B | |
| +7.72% | 43.89B | |
| +7.86% | 38.07B |
- Stock Market
- Equities
- 688626 Stock